New immune targets identified in glioblastoma: CD44 and TNFSF14 may help guide future therapies

Glioblastoma (GBM) is the most aggressive and lethal form of brain cancer, with a median survival of only 15 months despite intensive treatment. Current therapies—including surgery, radiation, and chemotherapy—offer limited long-term benefit, and immune-based treatments have so far shown minimal success. The complexity of the tumor’s microenvironment and its ability to suppress immune responses contribute to the poor prognosis.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup